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Background: Hemodialysis patients with erythropoiesis-stimulating agent (ESA) hyporesponsiveness have
been a topic of active research. However, there have been no studies of ESA hyporesponsiveness among US
patients following the dramatic change in anemia management that resulted from the 2011 changes in ESA
product labeling and bundling of dialysis remuneration.
Study Design: Retrospective observational study.
Setting & Participants:We studied prevalent hemodialysis patients treated at a large dialysis organization
in calendar years 2012 to 2013 (N 5 98,972).
Predictor: ESA hyporesponsiveness, defined as 2 consecutive hemoglobin measurements , 10 g/dL
(every other week) with contemporaneous ESA dose . 7,700 U/treatment. Patients with ESA hypores-
ponsiveness were identified during the first quarter of 2012 and followed up through 2013 using intention-to-
treat principles.
Outcomes: Associations between the study exposure (ESA hyporesponsiveness) and mortality, missed
hemodialysis treatments, ESA and iron use, and hemoglobin levels were determined using generalized esti-
mating equations adjusting for imbalanced baseline covariates.
Results: At baseline, 12,361 (12.5%) patients were identified as having ESA hyporesponsiveness. The
mean hemoglobin level among patients with ESA hyporesponsiveness was w1 g/dL lower than in patients
without ESA hyporesponsiveness at baseline, narrowing over follow-up to 0.4 g/dL. Initially, mean ESA use
was approximately 3-fold greater for patients with ESA hyporesponsiveness than for those without ESA
hyporesponsiveness, decreasing to 2-fold greater at study end; iron use and missed hemodialysis
treatment rates were also greater among patients with ESA hyporesponsiveness throughout. ESA
hyporesponsiveness was associated with enhanced mortality risk versus non–ESA hyporesponsiveness:
adjusted incidence rate ratios were estimated at 2.24 (95% CI, 1.93-2.60) in the second quarter, gradually
decreasing to 1.48 (95% CI, 1.18-1.84) by study end.
Limitations: It is possible that an alternative ESA hyporesponsiveness definition may be optimal. As such,
the associations we observed may be conservative estimates of true relationships.
Conclusions: When using a contemporary definition at one point in time, ESA hyporesponsiveness was
potently and persistently associated with greater mortality, greater iron and ESA use, and lower hemoglobin
levels compared to non–ESA hyporesponsiveness.
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0272-6386
http://dx.doi.org/10.1053/j.ajkd.2016.05.031Kidney disease–related anemia is highly prevalentamong patients with end-stage renal disease and
is associated with signiﬁcant and debilitating morbidity,
as well as increased risk for mortality.1 In patients with
end-stage renal disease who undergo hemodialysis,
kidney disease–related anemia is typically treated with
both erythropoiesis-stimulating agents (ESAs) and
intravenous (IV) iron.2,3 These treatments have been the
standard of care for decades.
A signiﬁcant proportion of patients with kidney
disease–related anemia undergoing hemodialysis do
not respond as anticipated: either they cannot achieve
the targeted hemoglobin value or they require persis-
tently high ESA doses to achieve targets. The mecha-
nisms for reduced ESA responsiveness are not entirely
delineated, but evidence indicates mediating roles ofy Dis. 2016;68(5):763-771inﬂammation, iron deﬁciency (absolute or functional),
inadequate vitamin D,4 and underlying illnesses or
infections.5 Past studies have shown that greater ESA
hyporesponsiveness is associatedwith poor survival,6,7763
Luo et aland other studies have indicated that high ESA doses
may contribute to poor patient outcomes.2,3,8-11
Although prior studies of hyporesponsiveness did not
conform to a single consensus deﬁnition (no such
deﬁnition exists), all based ESA hyporesponsiveness
on ESA doses and/or hemoglobin levels, each evalu-
ated with respect to population distributions.
In 2011, there were marked changes in ESA dosing
practices among US hemodialysis patients. During
that year, there were changes to both US dialysis
remuneration policy for injected drugs for dialysis
patients and ESA product labeling, resulting in
marked ESA dose reductions for the treatment of
kidney disease–related anemia.12-14 In parallel, the
distribution of hemoglobin levels shifted downward
in the US dialysis population. Because ESA hypo-
responsiveness is deﬁned with respect to ESA dose
and hemoglobin levels, it is unclear whether ﬁndings
from these prior studies pertain in contemporary
nephrology anemia treatment practice: even recently
published studies of ESA hyporesponsiveness have
considered data from prior to 2011.15
We undertook the present study to identify a
deﬁnition of ESA hyporesponsiveness that is relevant
in today’s ESA dosing environment and to use
that deﬁnition to examine the prevalence of ESA
hyporesponsiveness and the association of ESA
hyporesponsiveness with clinical (hemoglobin con-
centrations, mortality and missed hemodialysis treat-
ment rates) and health care utilization (cumulative
ESA and iron use) outcomes.
METHODS
Data and Patient Cohort
Data for our retrospective study were abstracted from the
electronic health record of a large dialysis organization. The large
dialysis organization data set contains information about patient
demographics, disease history, comorbid conditions, dialysis-
speciﬁc information for each treatment session, laboratory results
such as hemoglobin levels, and IV anemia medications adminis-
tered at dialysis sessions (ESAs and iron).
Patients eligible for the analysis were 18 years or older, were not
Veterans Affairs beneﬁciaries (contractual stipulation), received
in-center hemodialysis at the large dialysis organization, and had a2012 202011
patient 
demographics
exposure follow-up
X X X X X X X
Figure 1. Study schematic. For the descriptive portion of th
erythropoiesis-stimulating agent (ESA) hyporesponsiveness accordin
8 calendar quarters (indicated by Xs). For the associative analysis (pr
information was collected in the 90 days leading up to January 1, 2
ascribed ESA hyporesponsiveness status if they met definition 4
were assessed through December 31, 2013 (dashed grey line).
764dialysis vintage of 6 months or longer to allow for stabilization of
ESA dose following dialysis therapy initiation. In a majority of
patients, ESA and iron dosing followed one of the large dialysis
organization’s clinical protocols: for each, 3 protocols of varying
intensity are in place; physicians may choose among these or treat
off-protocol. In rare cases in which patients were treated with
agents other than epoetin alfa (eg, darbepoetin alfa) or other dosing
frequencies were used, ESA dose units were converted based on
manufacturer recommendations.16
For descriptive analyses, we considered the point prevalent
cohort of eligible patients at the start of each of 8 consecutive
calendar quarters from quarter 1 (Q1), 2012, through Q4, 2013
(Fig 1). Within each cohort, we calculated the point prevalence of
ESA hyporesponsiveness using each of 5 candidate deﬁnitions:
(1) 2 most recent hemoglobin measurements, separated by 141
days, both ,10 g/dL; (2) 2 most recent hemoglobin measure-
ments, separated by 141 days, both ,9.5 g/dL; (3) ESA dose .
7,700 U/treatment (this corresponds to the 80th percentile for dose
among the cohort and is approximately equivalent to a dose of
23,100 U/wk); (4) meets criteria for deﬁnitions 1 and 3; and (5)
meets criteria for deﬁnitions 2 and 3. Point prevalence was deﬁned
as the number of patients affected on the ﬁrst date of the quarter
divided by the number of patients in total.
For associative analyses, we considered the point prevalent
cohort of eligible patients at the start of Q1 in 2012. Exposure status
was assigned as ESA hyporesponsiveness or non–ESA hypores-
ponsiveness based on whether the patient met deﬁnition 4 of ESA
hyporesponsiveness at any point during Q1 in 2012 (Fig 1). Patients
were followed forward in historical time until the earliest of death,
loss to follow-up (transfer of care, transplantation, or withdrawal
from dialysis therapy), or end of study (December 31, 2013).
Baseline patient characteristics for the associative analysis (eg,
demographics and comorbid conditions) were determined as of the
start of Q1 2012; described as means, standard deviations, me-
dians, interquartile ranges, counts, and proportions; and compared
using t tests, Wilcoxon rank sum tests, and c2 tests, as dictated by
data type. Continuous patient baseline variables and mean medi-
cation dosages were determined using data available up to 90 days
prior to January 1, 2012 (study initiation). In rare instances for
which patient data were not available in the prior quarter, January
2012 data were used to capture baseline variables. During follow-
up, ESA use was analyzed on a monthly basis as mean dose
administered per dialysis session, considering all attended dialysis
treatments (ie, opportunities to receive ESA) so as to account for
treatments with zero dose. However, extra dialysis treatments
(including isolated ultraﬁltration sessions) were not considered
because ESA is not administered during these. Hemoglobin level
was calculated on a monthly basis during follow-up as the mean of
all measurements made during the month (typically 2). On a
monthly basis during follow-up, IV iron use was considered as the
cumulative dose administered during the month. Deaths were13
Descriptive analysis (cross-sectional)
Associative analysis (longitudinal)
X
e analysis (presented in Table 1), the point prevalence of
g to 5 candidate definitions was considered at the beginning of
esented in Tables 2 and 3 and Figs 2 and 3), patient demographic
012 (through January 30 if required; black line). Patients were
at any time during quarter 1 2012 (solid grey line). Outcomes
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ESA Hyporesponsivenessdetermined on a quarterly basis during follow-up and expressed as
rates: number of deaths during the quarter divided by cumulative
time at risk during the quarter. Missed hemodialysis treatments
were assessed because they are: (1) important clinical events in
their own right, (2) important economic levers for dialysis pro-
viders, and (3) surrogate indicators for acute health events that are
not well captured in standard data sources such as claims (ie, due
to delays) and electronic health records (ie, due to limited sensi-
tivity). Missed hemodialysis treatments were considered on a
quarterly basis during follow-up and expressed as rates.
Statistical Comparisons
Associations of ESA hyporesponsiveness status with outcomes
of interest were estimated using generalized estimating equation
(GEE) models to account for longitudinally correlated response
data. All GEE models considered the main effect of exposure
status (ESA hyporesponsiveness), time, and a 1-way ESA
hyporesponsiveness–by-time cross-product term, the latter to ac-
count for differences over time in the association between expo-
sure groups. The quasi-likelihood under the independence model
criterion approach was used to select a working correlation
structure. Demographic, comorbid condition, and clinical cova-
riates that were imbalanced between exposure groups and had
observed associations with the outcomes of interest on bivariable
testing were considered for inclusion in the models. Priority was
given to variables with the most clinical signiﬁcance. In rare cases
in which including a particular variable resulted in the failure of
the model to converge, we recharacterized the variable to reduce
the possibility of data separation. If this remedy failed, the variable
was not used in the model. Thus, the list of covariates adjusted for
differed slightly for each outcome analyzed.
Associations of ESA hyporesponsiveness status with hemo-
globin levels and the use of ESA and IV iron were estimated by
GEE models using an identity link, autoregressive correlation
structure, and Gaussian distribution, and associations of ESA
hyporesponsiveness status with mortality and missed hemodialysis
treatment rates were estimated by GEE models using a log link,
exchangeable correlation structure, and Poisson (mortality) or
negative binomial (missed treatments) distribution, respectively.
For ESA, the response variable was divided by 100 and its
rescaled value was used in the model to improve numeric stability.
Estimates were back converted and displayed on the native scale.Table 1. Point Prevalence of ESA Hyporesponsivene
ESA Hy
1. Two Most Recent
Hb Measurements,
Separated by 141 d,
Both ,10 g/dL
2. Two Most Recent H
Measurements, Separat
by 141 d, Both ,9.5 g/
Q1 2012 (N5 98,972) 29,287 (29.6) 14,431 (14.6)
Q2 2012 (N5 101,808) 28,195 (27.7) 13,681 (13.4)
Q3 2012 (N5 103,058) 27,199 (26.4) 13,217 (12.8)
Q4 2012 (N5 103,549) 25,884 (25.0) 12,425 (12.0)
Q1 2013 (N5 103,899) 28,306 (27.2) 13,724 (13.2)
Q2 2013 (N5 105,271) 27,475 (26.1) 13,134 (12.5)
Q3 2013 (N5 106,998) 29,239 (27.3) 14,139 (13.2)
Q4 2013 (N5 104,742) 23,465 (22.4) 11,265 (10.8)
Note: Values are given as number (percentage).
Abbreviations: ESA, erythropoiesis-stimulating agent; Hb, hemogl
aAt the large dialysis organization, ESA treatment is provided almo
cases in which patients are treated with other agents (eg, darbepoe
verted as described in Methods.
Am J Kidney Dis. 2016;68(5):763-771All statistical analyses were conducted using SAS, version 9.3
(SAS Institute Inc).
Compliance and Patient Protections
We conducted our observational study retrospectively using
deidentiﬁed patient data; therefore, according to 45 CFR part 46
from the US Department of Health and Human Services, this study
was exempt from institutional review board or ethics committee
approval. We adhered to the Declaration of Helsinki and informed
consent was not required.
RESULTS
Candidate Deﬁnitions of ESA Hyporesponsiveness
The point prevalence (schema in Fig 1) of ESA
hyporesponsiveness according to each of the 5
candidate deﬁnitions is presented in Table 1. Between
Q1 2012 and Q4 2013, prevalence ranged from 29.6%
to 22.4% using deﬁnition 1, 14.6% to 10.8% using
deﬁnition 2, 25.4% to 22.2% using deﬁnition 3,
12.5% to 9.0% using deﬁnition 4, and 7.7% to 5.6%
using deﬁnition 5. Deﬁnition 4 was selected because
it most closely aligned with prior deﬁnitions
conceptually and in terms of anticipated prevalence of
ESA hyporesponsiveness (w10%).15,17
Patient Demographics
For longitudinal associative analyses (schema in
Fig 1), we characterized patients as having or not
having ESA hyporesponsiveness based on whether
they met deﬁnition 4 at any time point during Q1 2012.
Baseline characteristics of patients with and without
ESA hyporesponsiveness are provided in Table 2. As
anticipated, median per-treatment ESA use was higher
among patients with ESA hyporesponsiveness than
those without (7,000 vs 1,742 U/treatment), and mean
monthly hemoglobin concentration was lower
(9.9 vs 11.2 g/dL). Beyond these implicit differencesss According to Each of 5 Candidate Definitions
poresponsiveness Definition
b
ed
dL
3. ESA Dose
.7,700 U/Treatmenta
4. Meets Criteria for
Definitions 1 and 3
5. Meets Criteria for
Definitions 2 and 3
25,107 (25.4) 12,361 (12.5) 7,590 (7.7)
24,956 (24.5) 11,975 (11.8) 7,324 (7.2)
24,608 (23.9) 11,483 (11.1) 7,109 (6.9)
23,340 (22.5) 10,537 (10.2) 6,433 (6.2)
23,959 (23.1) 11,530 (11.1) 7,138 (6.9)
23,542 (22.4) 11,117 (10.6) 6,895 (6.6)
23,900 (23.4) 11,690 (10.9) 7,267 (6.8)
23,290 (22.2) 9519 (9.0) 5,901 (5.6)
obin; Q, quarter.
st exclusively in the form of 3-times-weekly epoetin alfa. In rare
tin alfa) or other dosing frequencies are used, doses were con-
765
Table 2. Baseline Characteristics of ESA Hyporesponsive and Non2Hyporesponsive Patients
ESA Hyporesponsiveness
(n 5 12,361)
ESA Non2Hyporesponsiveness
(n 5 86,611) P
Age, y ,0.001
Mean 59.56 14.9 62.3 6 14.8
Median 60 [50-70] 63 [53-73]
Female sex 5,909 (47.8) 39,124 (45.2) ,0.001
Race ,0.001
White 4,004 (32.4) 30,965 (35.8)
Black 5,666 (45.8) 32,330 (37.3)
Hispanic 1,803 (14.6) 16,119 (18.6)
Asian 403 (3.3) 3,326 (3.8)
Unknown/missing 485 (3.9) 3,871 (4.5)
Vascular access ,0.001
Arteriovenous fistula 6,872 (55.6) 53,741 (62.1)
Arteriovenous graft 2,872 (23.2) 17,755 (20.5)
Central venous catheter 2,502 (20.2) 12,314 (14.2)
Dialysis vintage ,0.001
6-12 mo 2,243 (18.2) 17,368 (20.1)
$13 mo 10,118 (81.9) 69,243 (80.0)
Postdialysis weight, kg 0.9
Mean 79.86 23.3 79.8 6 22.4
Median 75 [64-92] 76 [64-92]
Cause of ESRD ,0.001
Diabetes 5,432 (43.9) 39,704 (45.8)
Hypertension 3,815 (30.9) 26,916 (31.1)
Other 3,114 (25.2) 19,991 (23.1)
Charlson Comorbidity Index score ,0.001
Mean 5.46 2.0 5.5 6 1.9
Median 5 [4-7] 6 [4-7]
Cancer 383 (3.1) 1,600 (1.9) ,0.001
Cerebrovascular disease 101 (0.8) 645 (0.7) 0.4
COPD 612 (5.0) 3,313 (3.8) ,0.001
Congestive heart failure 1,797 (14.5) 10,405 (12.0) ,0.001
Coronary artery disease 943 (7.6) 6,060 (7.0) 0.01
Diabetes 8,484 (68.6) 59,201 (68.4) 0.5
Gastrointestinal bleeding 188 (1.5) 855 (1.0) ,0.001
HIV/AIDS 106 (0.9) 322 (0.4) ,0.001
Hypertension 4,356 (35.2) 28,053 (32.4) ,0.001
Non2kidney disease2related anemiaa 263 (2.1) 722 (0.8) ,0.001
Peripheral vascular disease 359 (2.9) 2,303 (2.7) 0.1
IV antibioticsb 1,097 (8.9) 3,680 (4.3) ,0.001
Serum albumin,b g/dL ,0.001
Mean 3.896 0.48 4.06 6 0.38
Median 3.9 [3.60-4.20] 4.10 [3.90-4.30]
Kt/Vb ,0.001
Mean 1.676 0.33 1.71 6 0.31
Median 1.64 [1.47-1.84] 1.68 [1.52-1.87]
IV vitamin D use,b mg/treatment ,0.001
Mean 2.526 2.82 2.28 6 2.54
Median 1.85 [0.50-3.50] 1.69 [0.50-3.21]
IV iron use,b mg/mo ,0.001
Mean 1896 209 163 6 172
Median 200 [0-200] 200 [0-200]
(Continued)
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Table 2 (Cont’d). Baseline Characteristics of ESA Hyporesponsive and Non2Hyporesponsive Patients
ESA Hyporesponsiveness
(n 5 12,361)
ESA Non2Hyporesponsiveness
(n 5 86,611) P
ESA use,b U/treatment ,0.001
Mean 7,9936 5,515 2,7316 3,120
Median 7,000 [3,789-11,825] 1,742 [677-3,723]
Parathyroid hormone,b ng/mL ,0.001
Mean 5476 550 472 6 382
Median 406 [258-620] 383 [256-560]
Hemoglobin,b g/dL ,0.001
Mean 10.1 6 1.1 11.26 1.0
Median 9.9 [9.3-10.8] 11.1 [10.6-11.7]
Serum ferritin,b ng/mL ,0.001
Mean 8196 499 783 6 396
Median 737 [476-1,041] 740 [510-992]
Transferrin saturation,b % ,0.001
Mean 31.66 16.5 33.6 6 13.9
Median 27.0 [21.0-37.0] 31.0 [24.0-40.0]
Note: ESA hyporesponsiveness determined as per definition 4 (see Table 1): 2 most recent hemoglobin measurements, separated
by 141 days, both,10 g/dL, and ESA dose.7,700 U/treatment. Values for categorical variables are given as percentages; values for
continuous variables are given as mean 6 standard deviation or median [interquartile range].
Abbreviations: COPD, chronic obstructive pulmonary disease; ESA, erythropoiesis-stimulating agent; ESRD, end-stage renal dis-
ease; IV, intravenous; HIV, human immunodeficiency virus.
aIncludes sickle cell anemia, monoclonal gammopathy, or myelodysplastic syndrome.
bPatient baseline continuous variables were determined using results obtained up to 90 days prior to the beginning of the identifi-
cation window (January 1, 2012), and patients were followed forward until censoring or study end. In rare instances, when there were
no claims data available prior to January 1, 2012, January 2012 data were used to capture baseline variables.
ESA Hyporesponsiveness(ie, as would be anticipated based on the ESA
hyporesponsiveness deﬁnition), patients with ESA
hyporesponsiveness were younger (mean age, 59.5
vs 62.3 years) and a higher proportion were African
American (45.8% vs 37.3%), more frequently used
central venous catheters for hemodialysis (20.2% vs
14.2%), and less frequently had arteriovenous ﬁs-
tulas (55.6% vs 62.1%) compared with patients
without ESA hyporesponsiveness. Patients with ESA
hyporesponsiveness were also more frequently
treated with antibiotics in the 90 days prior to
January 1, 2012 than patients without ESA hypo-
responsiveness (8.9% vs 4.3%). Other statistically
signiﬁcant differences were observed, but in general,
the magnitude of these remaining differences was
small.
Anemia and Anemia Medication Use
Using intention-to-treat principles, we followed
patients’ indices of anemia management forward
in historical time based on their initial ESA
hyporesponsiveness or non–hyporesponsiveness
characterization. Figure 2 displays mean adjusted
and unadjusted ESA use, hemoglobin concentra-
tions, and IV iron use during the 24 months of
follow-up for the ESA hyporesponsive and non–
hyporesponsive groups. During month 1, meanAm J Kidney Dis. 2016;68(5):763-771adjusted per-treatment ESA use was 9,586 units for
patients with ESA hyporesponsiveness and 2,904
units for patients without ESA hyporesponsiveness
(Fig 2A). During the course of study, mean ESA use
declined among the ESA hyporesponsive group (to
7,951 U/treatment by the last month of follow-up)
but remained essentially stable among the non–
hyporesponsive group (3,009 U/treatment in the last
month of follow-up). The resulting between-group
difference thus narrowed during follow-up (from
w3-fold to w2-fold) and remained clinically and
statistically signiﬁcant at all times (P , 0.001 for
each month of follow-up). During month 1, adjusted
mean hemoglobin concentrations were 9.8 g/dL for
patients with ESA hyporesponsiveness and 10.8 g/dL
for patients without (Fig 2B). During the course
of study, hemoglobin levels increased among pa-
tients in the ESA hyporesponsive group (to 10.3 g/dL
in the last month of study) and remained essentially
constant among the non–hyporesponsive group
(10.8 g/dL in the last month of study). Between-
group differences in hemoglobin levels were highly
statistically signiﬁcant in every month (P , 0.001).
The ESA hyporesponsive group had greater IV iron
use than the non–hyporesponsive group in every
month, but the magnitude of difference was modest
(Fig 2C).767
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Figure 2. (A) Mean per-treatment erythropoiesis-stimulating agent (ESA) use, (B) monthly hemoglobin (Hb) levels, and (C) monthly
intravenous (IV) iron use during follow-up. (A) Per-treatment ESA use mean values were adjusted for baseline differences in sex, age,
race, cause of end-stage renal disease (ESRD), dialysis vintage, vascular access, cancer, parathyroid hormone level, albumin level,
and Charlson Comorbidity Index score. The interaction between exposure and month was significant, P , 0.001. Differences between
ESA hyporesponsive (ESAhr) and non-ESAhr mean monthly per-treatment ESA use were significant in all months, P , 0.001. (B)
Monthly Hb mean values were adjusted for baseline differences in sex, age, race, cause of ESRD, dialysis vintage, vascular access,
cancer, parathyroid hormone level, albumin level, and Charlson Comorbidity Index score. The interaction between exposure and
month was significant, P , 0.001. Differences between the ESAhr and non-ESAhr cohorts’ Hb were significant in all months,
P, 0.001. (C) Monthly IV iron use mean values were adjusted for baseline differences in age, sex, race, Charlson Comorbidity Index
score, serum albumin level, parathyroid hormone level, antibiotic use, peripheral vascular disease, hypertension, human immunode-
ficiency virus/AIDS, gastrointestinal bleed, coronary artery disease, chronic obstructive pulmonary disease, congestive heart failure,
cancer, vascular access, dialysis vintage, and cause of ESRD. Differences between non-ESAhr and ESAhr IV iron use were significant
in all months, P , 0.001.
Luo et alClinical Outcomes
Again using intention-to-treat principles, we fol-
lowed patients’ clinical outcomes forward in time
based on their initial ESA hyporesponsiveness
characterization. Figure 3 displays adjusted and
unadjusted incidence rate ratios (IRRs) for mortality
by quarter over the study. During Q1, the unad-
justed IRR for mortality among patients with ESA
hyporesponsiveness was not signiﬁcantly different
from that of patients without ESA hyporesponsive-
ness (Fig 3A). Thereafter, mortality risk increased
among patients with ESA hyporesponsiveness and
remained signiﬁcantly greater than that of their non–
hyporesponsive counterparts for the duration of
follow up. Unadjusted IRRs peaked at 2.19 (95%
conﬁdence interval [CI], 2.01-2.39) during Q2 and
gradually declined, reaching a plateau at w1.5
during the last 3 quarters of follow-up (Q8: unad-
justed IRR, 1.45; 95% CI, 1.29-1.64). Adjusted
IRRs for mortality were identical in trend and
similar in values to unadjusted IRRs during the
study period (Fig 3B).
Table 3 reports the adjusted rate of missed hemo-
dialysis treatments during follow-up. The missed
treatment rate was signiﬁcantly higher among patients
with ESA hyporesponsiveness at all points during
follow up. During Q1, patients with ESA hypores-
ponsiveness had an average of 2.64 more missed
hemodialysis treatments per quarter (P , 0.001). The
magnitude of association attenuated modestly during
the course of follow-up, reaching a plateau at
1.47 incremental missed hemodialysis treatment per
month over Q5 through Q8. The reported associations
between ESA hyporesponsiveness status, mortality,768and missed hemodialysis treatments were not mate-
rially different when 985 patients with identiﬁed
non–kidney disease–related causes of anemia
(sickle cell anemia, monoclonal gammopathy, and
myelodysplastic syndrome) were excluded from
analysis.
DISCUSSION
ESA hyporesponsiveness is a physiologic condi-
tion that is identiﬁed clinically by a combination of
somewhat arbitrary cutoffs in terms of ESA dose and
hemoglobin concentration. Although ﬁrst-line treat-
ments for kidney disease–related anemia, namely
ESA and IV iron, have been the standard of care for
decades,18,19 normative practices with respect to ESA
dosing and hemoglobin level targeting have changed
in recent years in response to ﬁnancial and regulatory
events.12,13 It therefore could be anticipated that the
clinical expression of ESA hyporesponsiveness might
change. In this study, we sought to identify an oper-
ational deﬁnition of ESA hyporesponsiveness that is
relevant in contemporary clinical practice. Criteria for
deﬁning ESA hyporesponsiveness have varied across
studies of hemodialysis patients, and the deﬁnitions
used have taken into consideration both ESA dose
and hemoglobin concentration or hematocrit,20,21
including the duration of elevated ESA dosing
requirement,15,22 or have used the erythropoietin
resistance index (weekly weight-adjusted ESA dose
[U/kg/wk] divided by hemoglobin concentration
[g/dL]).23 In hemodialysis patients, the prevalence of
ESA hyporesponsiveness has been estimated at 5%
to 15%.15,17,20 In our analysis, we determined that
among candidate deﬁnitions, the combination of ESAAm J Kidney Dis. 2016;68(5):763-771
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Figure 3. Quarterly mortality incidence rate ratios (IRRs) during follow-up for patients with versus without erythropoiesis-stimulating
agent hyporesponsiveness at baseline. Shown are the (A) unadjusted and (B) adjusted IRRs with 95% confidence intervals (CIs). Mor-
tality rates, estimated using general estimating equation Poisson models with exchangeable correlation structure, were adjusted for
differences at baseline in age, sex, cause of end-stage renal disease, dialysis vintage, vascular access, cancer, cerebrovascular dis-
ease, heart failure, chronic obstructive pulmonary disease, coronary artery disease, gastrointestinal bleeding, human immunodefi-
ciency virus/AIDS, peripheral vascular disease, intravenous (IV) antibiotic use, dry weight, serum ferritin level, saturated transferrin,
parathyroid hormone level, albumin level, IV vitamin D use, and Charlson Comorbidity Index score. The interaction between exposure
and quarter was significant, P , 0.001. In determining all IRRs, ESA non-hyporesponsiveness rates served as the referent.
ESA Hyporesponsivenessdose . 7,700 U/treatment (corresponding to a weekly
dose . 23,100 units) along with hemoglobin level
, 10 g/dL on each of 2 successive bimonthly mea-
surements met with prior expectations with regard to
the prevalence of ESA hyporesponsiveness: approxi-
mately 9% to 12% of hemodialysis patients receiving
ESA therapy at any time.
Older studies using era-appropriate deﬁnitions have
demonstrated that ESA hyporesponsiveness is asso-
ciated with death, kidney transplant failure, vitamin D
deﬁciency, and hemoglobin level variability.11,24,25 It
is notable that the presence of ESA hyporesponsive-
ness, as deﬁned using our operational deﬁnition, was
likewise associated with enhanced mortality risk
compared to its absence. It is also noteworthy that theTable 3. Adjusted Missed Hemodialysis Treatment Rates During
at Base
Quarter Postbaseline
Adjusted Quarterly Rate (9
ESA Hyporesponsiveness ESA No
1 4.75 (4.64-4.85)
2 4.46 (4.35-4.58)
3 4.39 (4.28-4.51)
4 6.32 (6.20-6.44)
5 4.75 (4.63-4.88)
6 4.22 (4.10-4.34)
7 4.40 (4.27-4.53)
8 7.42 (7.28-7.57)
Abbreviations: CI, confidence interval; ESA, erythropoiesis-stimula
aMissed treatments per quarter. Adjusted rate estimates using g
exchangeable correlation structure were adjusted for differences at
vascular access, cancer, cerebrovascular disease, heart failure, ch
gastrointestinal bleeding, human immunodeficiency virus/AIDS, per
serum ferritin level, saturated transferrin, parathyroid hormone le
Comorbidity Index score. The interaction between exposure and qua
Am J Kidney Dis. 2016;68(5):763-771mortality association was highly potent (1.5- to
2.5-fold) and the association persisted for at least
2 years after ESA hyporesponsiveness status was
ascribed.
It is unclear whether ESA hyporesponsiveness is a
causal determinant of mortality (perhaps due to toxic
effects of resultantly high doses of ESA) or whether
the excess in mortality relates to the conditions that
render patients ESA hyporesponsive, or other differ-
ences between patients with ESA hyporesponsiveness
and patients without. This study cannot make
that distinction. We note that among measurable
differences versus patients without ESA hypores-
ponsiveness, patients with ESA hyporesponsiveness
had some characteristics that might favor positiveFollow-up for Patients With and Without ESA Hyporesponse
line
5% CI)a
Incidence Rate Difference (95% CI)n-Hyporesponsiveness
2.29 (2.27-2.32) 2.46 (2.32-2.52)
2.46 (2.43-2.49) 1.98 (1.86-2.07)
2.64 (2.61-2.68) 1.74 (1.65-1.83)
4.79 (4.76-4.83) 1.53 (1.41-1.65)
3.19 (3.16-3.23) 1.56 (1.47-1.74)
2.75 (2.71-2.78) 1.47 (1.41-1.65)
2.88 (2.84-2.91) 1.53 (1.44-1.71)
5.96 (5.92-6.01) 1.47 (1.35-1.68)
ting agent.
eneralized estimating equations negative binomial model with
baseline in age, sex, cause of end-stage renal disease, vintage,
ronic obstructive pulmonary disease, coronary artery disease,
ipheral vascular disease, intravenous antibiotic use, dry weight,
vel, albumin level, intravenous vitamin D use, and Charlson
rter is significant, P, 0.001.
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Luo et alprognosis (younger and more likely to be African
American) and other characteristics that might favor a
negative prognosis (greater catheter use and greater
antibiotic use). We controlled for such differences
analytically to the degree possible. However, because
the precise mechanisms underlying ESA hypores-
ponsiveness are not fully elaborated and due to data
limitations, we could not control for all factors that
rendered patients hyporesponsive and therefore
cannot assess causality. Clinical trials are needed to
assess whether and why ESA hyporesponsiveness
causes death. In the meantime, it can be said that ESA
hyporesponsiveness is a potent prognostic marker for
risk of death.
We also found that ESA hyporesponsiveness was
potently and persistently associated with a greater rate
of missed hemodialysis treatments. As such, ESA
hyporesponsiveness is highly relevant to dialysis
providers economically because foregone revenue
from missed treatments is among their largest variable
(opportunity) costs.26 Moreover, because missed he-
modialysis treatments frequently result from hospi-
talizations, it is likely that ESA hyporesponsiveness is
associated with greater rates of hospital admissions. If
true, this would have broader economic implications
for payors and taxpayers. However, limitations in the
source data prevented empirical conﬁrmation of the
ESA hyporesponsiveness–hospitalization link (ie,
claims data needed to identify hospitalizations
become available only after a several-year lag and are
not yet available for the period being studied), and
further study is needed in this area.
As implied by the operational deﬁnition, baseline
ESA use was greater (w3-fold) and hemoglobin
levels were lower (w1.0 g/dL) among patients with
ESA hyporesponsiveness than patients without ESA
hyporesponsiveness. As anticipated, these differ-
ences attenuated during the course of follow-up.
This attenuation was likely derived from at least
2 factors. First, patients with ESA hyporesponsive-
ness due to acute illness recover from these illnesses
and restitute ESA responsiveness. Second, among
patients with ESA hyporesponsiveness, there is a
selective attrition of the sickest patients. In general,
these will be the patients with the greatest ESA use
and lowest hemoglobin levels. As a result, over time,
mean ESA use will decrease and mean hemoglobin
level will increase. Collectively, these factors are
referred to as regression to the mean and can be
anticipated in any instance in which eligibility is
contingent on disease severity. Considering this, it
is remarkable that the separation in ESA use and
hemoglobin levels persisted and remained potent
(about 2-fold and 0.6 g/dL, respectively) for at least
2 years after ESA hyporesponsiveness status was
ascribed.770As noted previously, the reasons that patients
had ESA hyporesponsiveness are not known, both
because the spectrum of antecedent causes is not fully
elucidated and because many of the causes that are
known are not reliably captured in clinical databases.
One obvious potential cause is iron deﬁciency. These
data suggest that absolute iron deﬁciency was not a
primary determinant of ESA hyporesponsiveness in
our population.3,27 Baseline ferritin levels were higher
among patients with ESA hyporesponsiveness than
those without, and patients with ESA hypores-
ponsiveness also received greater amounts of IV iron
throughout follow-up. We cannot assess the impact of
functional iron deﬁciency on ESA hyporesponsive-
ness because of the interdependent nature of pathways
mediating ESA responsiveness and iron meta-
bolism.28 However, it is worth noting that, in our
study, transferrin saturation percentage values were
lower among patients with ESA hyporesponsiveness
than among patients without ESA hyporesponsive-
ness, which may suggest a link.
Some study limitations have already been noted;
however, one limitation bears particular mention.
Although we attempted to formulate informed
candidate deﬁnitions of ESA hyporesponsiveness
based on our experience and literature precedent, it is
possible that an alternative deﬁnition may be optimal
(ie, more tightly associated with patient outcomes).
As such, the associations we observed may be con-
servative estimates of true relationships.
This study represents the ﬁrst analysis of ESA
hyporesponsiveness since the 2011 changes in the
US ESA labels and reimbursement policy and the
concomitant changes in ESA dosing practices. In the
context of these changes, we identiﬁed a new
operational deﬁnition of ESA hyporesponsiveness
that is conceptually aligned with the underlying
construct, meets with expectations regarding its
historical prevalence, and is relevant in contempo-
rary practice. Using this new deﬁnition, we observed
potent and persistent associations of ESA hypores-
ponsiveness with lower hemoglobin concentrations
and greater rates of ESA use, missed hemodialysis
treatments, and mortality, as had been reported
previously using older deﬁnitions of ESA hypores-
ponsiveness. At a minimum, ESA hyporesponsive-
ness, as deﬁned here, can be considered to be a
prognostic marker with important clinical and
economic implications. Further studies are needed
to assess causality and, as warranted, therapeutic
intervention.
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